Celldex Therapeutics, Inc.
CLDX
$21.85
-$0.083-0.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.79M | 7.56M | 7.02M | 9.98M | 8.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.79M | 7.56M | 7.02M | 9.98M | 8.30M |
| Cost of Revenue | 199.01M | 184.50M | 163.55M | 147.04M | 136.31M |
| Gross Profit | -193.22M | -176.94M | -156.53M | -137.06M | -128.01M |
| SG&A Expenses | 41.53M | 40.27M | 38.55M | 37.12M | 35.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 240.54M | 224.77M | 202.10M | 184.15M | 171.59M |
| Operating Income | -234.75M | -217.21M | -195.08M | -174.18M | -163.29M |
| Income Before Tax | -199.61M | -178.85M | -157.86M | -154.08M | -150.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -199.61 | -178.85 | -157.86 | -154.08 | -150.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -199.61M | -178.85M | -157.86M | -154.08M | -150.22M |
| EBIT | -234.75M | -217.21M | -195.08M | -174.18M | -163.29M |
| EBITDA | -231.40M | -213.94M | -191.90M | -171.06M | -160.19M |
| EPS Basic | -3.01 | -2.70 | -2.45 | -2.57 | -2.74 |
| Normalized Basic EPS | -1.88 | -1.69 | -1.53 | -1.45 | -1.56 |
| EPS Diluted | -3.01 | -2.70 | -2.45 | -2.57 | -2.74 |
| Normalized Diluted EPS | -1.88 | -1.69 | -1.53 | -1.45 | -1.56 |
| Average Basic Shares Outstanding | 265.42M | 265.05M | 257.54M | 243.21M | 224.18M |
| Average Diluted Shares Outstanding | 265.42M | 265.05M | 257.54M | 243.21M | 224.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |